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Prescribing psychotropic medication during the perinatal period: an overview of the 
2017 British Association for Psychopharmacology consensus guidance 
 
Abstract: 
The use of psychotropic medication in pregnant and breastfeeding women is an area of great 
challenge for both women with mental health problems and clinicians.  There are many uncertainties 
regarding risks of untreated illness on mother, fetus or infant as well as concerns over potential risks 
to the fetus or infant associated with use of psychotropic medications during pregnancy or 
breastfeeding.  The purpose of the guidelines is to provide advice regarding making decisions around 
treating mental illness in the perinatal period.  This article provides a summary and explanation of the 
consensus guidance. 
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Introduction 
Prescribing in the perinatal period is challenging for both patient and doctor.  Risks in utero, or via 
breast milk exposure to medication to the fetus and infant need to be balanced against the risks of 
untreated illness to both mother and child. 
Background of the guidelines 
The British Association of Psychopharmacology (BAP) produces evidence based guidelines for use of 
medication in patients with psychiatric disorders.  Given the extent of great uncertainty that exist in 
prescribing in the perinatal period, this is an area in which clinicians are perhaps particularly 
dependent on guidelines.  The guideline’s purpose is to give pragmatic guidance.  It was created 
following a consensus meeting with input from experts in the field of perinatal psychiatry, 
psychopharmacology, teratology, infant and child development and service user representatives.  As 
BAP were creating this guideline, the National Institute for Health and Clinical Excellence (NICE) were 
publishing revised perinatal guidelines CG192 (NICE, 2015).  Recognising that conflicting guidelines 
would be detrimental for clinicians and patients, BAP paused their work awaiting publication of NICE 
CG192.  After reviewing the new NICE guideline BAP continued to work on this guideline with the aim 
of complementing CG192 and providing practical clinical recommendations.  NICE CG192 clearly 
recommends shared decision making regarding options to treat or prevent mental illness and suggests 
that these discussions cover potential benefits of treatment, possible consequences of no treatment, 
possible harms from treatment and possible effects of changing or stopping treatment (NICE, 2015). 
Overview of the guidelines 
The BAP 2017 perinatal guidelines consists of four broad parts which seek to address the areas of 
discussion recommended by NICE CG192; risks of untreated illness, generic guidance on using 
medication in the perinatal period, benefits and harms associated with individual treatments and 
recommendations for the pharmacological management of specific disorders.  The scope of each of 
the four parts is described in Table 1.  The term ‘perinatal’ in these guidelines is used to include the 
period from preconception, through pregnancy and to the end of the first year postpartum. 
(McAllister-Williams et al, 2017). 
Table 1.  The four main areas of the BAP 2017 Guidance and the scope of each section. 
 Area of guidance Scope  
1. Risks of untreated illness  Describes the risk to mothers and their children 
of psychiatric illness and symptoms particularly 
when untreated 
2. Using medication in the perinatal 
period 
 
Discusses general principles of using medication 
in the perinatal period 
3. Benefits and harms associated with 
individual medication and treatments 
 
Reviews the risks associated with specific 
psychotropic medications and treatments. 
 
Includes antidepressants, anxiolytics, 
antipsychotics, lithium, anticonvulsant mood 
stabilisers, attention deficit hyperactivity 
disorder (ADHD) medications, substance misuse 
medications and neuromodulatory treatments. 
4. Recommendations for the 
pharmacological management of 
specific disorders 
Provides guidance on the management of 
psychiatric disorders in the perinatal period. 
 
Includes depression, anxiety disorders, bipolar 
disorder, psychosis, eating disorders, ADHD, 
substance misuse, personality disorders and 
acute behavioural disturbance,  
A summary of each section of the guidance is provided below. 
Overview of part 1: Risks of untreated illness 
General risks of untreated illness 
The risks of untreated illness in the perinatal period is underlined by the results of the Confidential 
Enquiry into maternal deaths.  Maternal suicide remains the leading case of direct deaths in the first 
year postpartum (Knight et al, 2017). 
Women with untreated mental illness in pregnancy are less likely to fully engage in antenatal care 
(Kim et al, 2006).  They are also more likely to misuse nicotine, alcohol and other substances which 
have their own negative impacts on pregnancy outcomes (Shah and Howard, 2006; Zhu and Valbo 
2002; Zuckermann et al 1989).  Furthermore there is an impact of untreated maternal mental illness 
on the rest of her family, including relationships with her partner and any other children.  Maternal 
depression is known to be a risk factor for postnatal paternal depression (Bradley and Slade, 2011; 
Burke, 2003). 
When considering the risks of untreated illness, it needs to be noted that much of the evidence 
available includes studies of women with symptoms of specific conditions and not necessarily meeting 
defined diagnostic criteria of particular disorders.  Furthermore, effects on offspring may be 
confounded by shared genetics rather than a pure effect of maternal illness in the perinatal period 
(McAllister-Williams et al, 2017). 
Risks related to specific untreated disorders 
Risks related to specific untreated disorders are described in Table 2 
Table 2: Risks related to specific untreated disorders. 
Untreated disorder Associated risks 
Untreated depression 
and untreated anxiety 
Preterm delivery and low birth weight (Alder et al, 2007; Grote et al, 2010) 
 
Risk of low birth weight increases with severity of depression (Steer et al, 
1992) 
 
Conduct disorder and ADHD symptoms in offspring (Glover, 2014) 
 
Poor engagement and bonding with infant leading to poor infant learning 
and cognitive development (Sutton et al, 2012) 
Untreated bipolar 
disorder 
High risk of relapse post partum 
 
Very high risk of puerperal psychosis (Wesseloo et al, 2016) 
Untreated 
schizophrenia 
Acute psychosis in first year postnatally (Munsk-Olsen et al 2009) 
 
Adverse obstetric and neonatal outcomes (Bennedsen et al 1999, 2001; 
Cannon et al, 2002; Dalman et al, 1999; Howard et al, 2003; Jablensky et 
al, 2005; Vigod et al, 2014) 
 
Untreated eating 
disorders 
Increased risk of perinatal depression and anxiety (Easter et al, 2015; 
Micali et al, 2011) 
 
In Anorexia Nervosa: low birth weight (Solmi et al, 2014) and small for 
gestational age babies (Micali et al, 2016) 
 
In Bulimia Nervosa/Binge eating disorder: large for gestational age babies 
(Linna et al, 2014) 
 
Untreated substance 
misuse 
Cannabis is associated with low birthweight and preterm labour (Metz 
and Stickrath, 2015) 
 
Opioids are associated with increased risk of fetal growth retardation, 
placental abruption, fetal death and preterm delivery (Center for 
Substance Abuse Treatment, 2008) 
 
Stimulants are associated with preterm labour, congenital abnormalities, 
intrauterine growth retardation (IUGR), placental abruption, low birth 
weight, neonatal death and SIDS (Debooy et al, 1993, Fox, 1994; Ryan et 
al 1987).  Also maternal complications of pre-eclampsia-like-syndrome, 
acute pulmonary oedema, seizures, cardiac arrhythmia and sudden death 
(Fox 1994; Ryan et al, 1987).  Use prior to delivery related to neonatal 
withdrawal (Chomchai et al, 2004, Smith et al, 2003) 
Overview of part 2: Use of medications in the perinatal period 
Whilst it may be tempting for clinicians to jump to section 4 to ascertain how to treat specific disorders 
in the perinatal period, it is paramount that section 2 is given careful consideration.  In this section 
general principles of using medication in the perinatal period are discussed.  The guidelines aim to 
convey that there is not a set recipe to follow when treating psychiatric disorders in the perinatal 
period, more a way of thinking that needs to be adopted.  The necessity of this approach owes to the 
lack of evidence and data in many areas of the field.  As such, risks are extremely hard to quantify.  
RCTs exploring use of psychotropic medication in pregnancy and breastfeeding are lacking due to 
difficulties with safely including this patient group.  Much information regarding risks of using 
psychotropic medication in the perinatal period is from population data and is retrospective and 
therefore has associated biases.  The confounding factors in this type of data include concomitant use 
of alcohol, substances and smoking as well as the underlying indication for the psychotropic 
medication.  For example, if adverse effects are reported for an antidepressant, it is difficult to 
establish if the effects are due to the drug itself or related to the underlying depression for which the 
drug was used. 
Furthermore, in the data available there tends to be an over-reporting of abnormalities compared to 
normal outcomes.  There is also the problem that minor and perhaps clinically insignificant 
abnormalities are reported along with serious malformations. 
Key principles of prescribing in the perinatal period 
There are several key principles of prescribing in the perinatal period.  These apply to all childbearing 
stages. 
1. Understanding a woman’s individual illness 
It is important to understand the nature, severity and course of the illness for the individual woman.  
Clinicians should be asking themselves “what is this illness like for this individual woman?”  Box 1 
highlights important information to consider to inform management choices. 
 How frequently does the illness relapse and what happens when it does? 
 What are the triggers for relapse? 
 What are the risks when unwell? 
 How helpful have medications been at treating illness and preventing relapse? 
 How long has the illness been in remission both on and off medication? 
 What has been the time to relapse on discontinuing medication? 
 What has been the time to recovery on restarting medication? 
 Is there a personal history of perinatal illness? 
 Is there a family history of severe perinatal illness? 
Box 1: Information to gather from an individual woman’s history to guide management options. 
2. Discussions with the woman (and partner) 
It is important to check if the woman and her family have been sufficiently educated about her illness, 
including if and how childbearing may affect its course.  It is also important to assess her (and 
potentially her partner’s) attitude to balancing risk of recurrence of mental illness against the safety 
of medication. 
3. Consideration of non-drug alternatives 
On weighing up the above factors then non drug options may be preferable. 
4. Rationalising existing treatment 
If a woman is on several different medications, it is advised to take a careful history of each drug and 
its effectiveness.  Try to prescribe as few drugs as possible at the lowest effective doses as determined 
in the individual patient.  Such doses may vary between women and it is important that individuals 
are not prescribed sub-therapeutic doses since this exposes the fetus to potential risks without 
conferring any therapeutic benefit to the woman.  It may be more appropriate to use a drug of known 
efficacy in a particular woman rather than a drug that is of unknown efficacy in her illness but carries 
a lower pregnancy risk. 
5. Provision of care and collaboration between services 
Due to the high risks associated with recurrence in the perinatal period women with a history of severe 
mental illness should be under the care of mental health services; perinatal mental health services 
where possible.  Given that women potentially access several services in the perinatal period, 
including primary care, maternity care, health visitors, neonatology and Children’s Services there 
needs to be close collaboration between all those involved in the care around her.  A perinatal mental 
health care plan should be drawn up and shared with relevant professionals.  This should include her 
care needs, ongoing pharmacological and psychosocial interventions, information about possible risks 
to the newborn, plans regarding breastfeeding and what the medication plans are for this phase.  Each 
professional’s roles in monitoring, providing intervention or coordinating care should be detailed.  
There should also be a plan that allows other professionals to identify when psychiatric review might 
be needed and how this can be accessed. 
 
Considerations specifically for the preconception period 
There should be discussions with all women of childbearing potential who are taking psychotropic 
medication or who have a history of severe mental illness about the implications of pregnancy and 
childbirth on both her mental health and associated risks of any medication she is taking.  Some 
medications are associated with very early teratogenicity, for example valproate or carbamazepine.  
With such medications adverse effects may have occurred before confirmation of pregnancy.  There 
should be discussions around contraception in such cases. In the case of valproate Medicines and 
Healthcare products Regulatory Agency (MHRA) Valproate Pregnancy Prevention Programme should 
be followed which includes ensuring highly effective contraception is in place.  Highly effective 
contraceptive options are those with less than 1% failure rate with typical use.  Highly effective 
contraceptive methods include long acting reversible contraceptives, copper intrauterine device, 
levonorgestrel intrauterine system, progestogen only implant (IMP) and female sterilisation  (MHRA, 
2018). 
Options available to women of childbearing potential or specifically planning a pregnancy could be to 
continue with their current medication regime, switch to a regime with fewer fetal or maternal 
adverse effects or discontinue medication completely.  Any discontinuation of medication should be 
done slowly to lessen the risk of relapse and allow monitoring of the woman’s mental state.  Women 
should be advised as to how long to continue contraception following discontinuation of medications 
based on half-lives and risks of teratogenicity.  
Specific considerations during pregnancy 
Women with a history of severe mental illness should be managed as a high risk pregnancy.  Other 
modifiable risk factors for example, substance use, smoking, alcohol and weight management should 
be addressed.  It is important to remember that smoking is the leading preventable cause of fetal 
morbidity and mortality in the UK (McAllister-Williams et al, 2017). 
The risks and benefits of continuing current medication regimes, changing or discontinuing should be 
discussed with the woman, taking into account the individual factors listed in Box 1.  Unless there is a 
good reason, changes in medication should be avoided in pregnancy.   If a woman is taking a 
medication known to carry a significant risk of fetal abnormalities then she should be offered early 
detailed ultrasound scanning.  Women taking second generation antipsychotic should be monitored 
for gestational diabetes and offered a glucose tolerance test (NICE, 2015). 
The risk of neonatal adaptation syndromes needs to be considered in the later stages of pregnancy.  
Most neonatal adaptation syndromes are mild and transient, but may be more pronounced in an 
intrauterine growth retarded (IUGR)  or sick baby. Consideration can be given to lowering the dose of 
medications close to the due date to reduce the risk of neonatal withdrawal, however given that 
delivery dates are not certain for many women this strategy risks a period of under-treatment for the 
mother and therefore potentially increases the risk of relapse. 
Specific intrapartum considerations 
It is recommended that women with severe mental illness should deliver in hospital.  The maternity 
team in hospital need to be aware of any medication issues for this period, for example, stopping 
lithium at the onset of labour to avoid maternal and neonatal toxicity (Newport 2005) or a woman 
may need to start an antipsychotic immediately following delivery if she is at risk of post-partum 
psychosis.   
Specific considerations postnatally and for breastfeeding 
The WHO recommends that ‘infants should be exclusively breastfed for the first 6 months of life to 
achieve optimal growth, development and health’ (WHO 2003).  Care should be taken when 
prescribing psychotropics to avoid over sedation, which may hinder both breastfeeding and ability to 
provide baby care.  There is very limited evidence regarding longer term outcomes in infants breastfed 
by mothers taking psychotropic medication.  There is little evidence to support timing of breastfeeding 
around medication doses, and indeed this may hinder breastfeeding.   
Similarly to pregnancy, an individual woman’s response to previous medication is the best guide for 
future treatment choices.  Where a mother is taking psychotropic medications, breastfed infants 
should be monitored for adverse effects including sedation or poor feeding. 
There needs to be extra caution applied to prescribing in breastfeeding women where the infant is 
sick, premature or the mother is taking multiple drugs. 
Overview of parts 3 and 4: Benefits and harms associated with individual medications 
and management of specific conditions 
Medication classes and specific drugs and treatments are considered in section 3.  They include 
antidepressants, anxiolytics, antipsychotics, lithium, anticonvulsant mood stabilisers, attention deficit 
hyperactivity disorder (ADHD) medications, substance misuse medications, neuromodulatory 
treatments.  For the category of drug each stage of the perinatal period is considered.  The guidance 
reviews effects on fertility, pregnancy and pregnancy outcomes. 
Section 4 of the guideline discusses management of specific conditions in the perinatal period.  When 
managing any condition perinatally it is important to refer back to the generic principles set out in 
section 2, ‘using medication in the perinatal period’.    
The sections of the guideline should be used in conjunction with each other to help clinicians develop 
a management plan for individual women with individual conditions.  We illustrate this with regard to 
the management of depression in the perinatal period. 
An example: management of depression in the perinatal period 
This worked example is divided into the three phases of pre conception, antenatal and postnatal care 
and illustrated in Table 3. 
Table 3: The management of depression in the perinatal period 
Perinatal Phase How to navigate the guidance 
Preconception Review section 2 'recommended principles for prescribing to women in 
the perinatal period' to inform individualised plan regarding commencing 
or continuing antidepressant treatment 
 
Review section 3 'antidepressants' in 'benefits and harm associated with 
individual medications' to guide choices 
 
No current antidepressants are absolutely contraindicated in pregnancy.  
SSRIs have the largest evidence base for reproductive safety and are often 
first line treatments in antidepressant naïve women. (Cleare et al, 2015; 
NICE, 2009). 
 
If a woman has had antidepressants before, be guided by principles in 
section 2 ‘recommended principles of prescribing to women in the 
perinatal period’ 
Antenatal All pre conception recommendations apply 
 
Generally do not suddenly discontinue medication due to risk of relapse 
and discontinuation syndrome 
 
Late in pregnancy, risk/benefit of PPHN needs to be considered 
 
Take into account intentions for breastfeeding thus avoiding the need to 
alter treatment postpartum 
Postnatal Antenatal depression leads to an increased risk of postnatal depression.  
Therefore if antidepressant treatment required in pregnancy likely to be 
of benefit postpartum. 
 
When a woman chooses to breastfeed, review ‘recommended principles 
of prescribing to women in the perinatal period: postnatally and 
breastfeeding’ 
 
Limitations of the guideline 
Data relevant to both this guideline and prescribing in the perinatal period in general are emerging 
constantly.  Therefore it is recommended that prescribers keep up to date with new information.  An 
example is that since this guideline was finalised there has been a further observational study 
published on the rates of major congenital malformations associated with anticonvulsants (Weston et 
al. 2016) and a case-controlled study of the risk of malformations with in utero exposure to metformin 
was generally reassuring (Given et al. 2018) – an important observation given the recommended use 
of metformin for antipsychotic induced weight gain (Cooper et al. 2016).  UKTIS (http://www.uktis.org) 
provides information on fetal risk.  Any modifications required to this guideline prior to its update and 
republication will be posted at http://www.bap.org.uk/perinatalupdates.  It is recommended that 
these BAP consensus guidelines are used in conjunction with the NICE perinatal guidelines (Nice 2015). 
Conclusions 
When managing any psychiatric disorder in the perinatal period, taking into account the woman’s 
individual illness history and response to treatment in paramount.  This information can then be used 
to tailor discussions around risks and benefits to her particular circumstances.  Whilst acknowledging 
that data on safety are limited, the risks of untreated illnesses must not be ignored.  Shared decision 
making with the woman is best practice and it is important to ensure that all relevant members of the 
team across different services involved in the woman’s care are aware of treatment plans and their 
role in management or coordination.  
 
 
 
Key messages 
 Data regarding risks and benefits of psychotropic medications in the perinatal period have 
many weaknesses, in particular the multiple confounding factors.  This makes definitive 
statements about risks and benefits impossible in many cases. 
 Untreated psychiatric illness in the perinatal period carries risks to the mother, fetus and 
infant. 
 When considering management plans there are no set ways to treat specific illnesses.  
Individual decisions should be based on the patient’s own illness, past treatment history 
and personal preferences. 
 Valproate is the only psychotropic contraindicated in women of childbearing potential when 
used for psychiatric indications, although there can be very rare exceptions. 
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